Trial | Treatment experience | Treatment type | Overall treatment duration (weeks) # | Treatment group | No of patients | Age (median) | Male sex no (%) | HCV genotype 1b no (%) | TVR treatment (weeks) | Peg-IFN-α dose (weeks) | RBV dose (mg/d) |
---|---|---|---|---|---|---|---|---|---|---|---|
[16] McHutchison et al. 2009 | Naïve | RGT | 12 | E | 17 | 49 | 12 (71) | 6 (35) | 12 | α2a: 180 μg | 1000-1200 |
RGT | 24 | D | 79 | 49 | 54 (68) | 17 (22) | 12 | α2a: 180 μg | 1000-1200 | ||
FLT | 48 | B | 79 | 50 | 48 (61) | 27 (34) | 12 | α2a: 180 μg | 1000-1200 | ||
Control | 48 | A | 75 | 49 | 43 (57) | 20 (27) | none | α2a: 180 μg | 1000-1200 | ||
[14] Hezode et al. 2009 | Naïve | RGT | 12 | E | 82 | 44 | 49 (60) | 45 (55) | 12 | α2a: 180 μg | 1000-1200 |
RGT | 24 | D | 81 | 46 | 54 (67) | 50 (62) | 12 | α2a: 180 μg | 1000-1200 | ||
RGT | 12 | NI | 78 | 45 | 43 (55) | 38 (49) | 12 | α2a: 180 μg | none | ||
Control | 48 | A | 82 | 45 | 46 (56) | 45 (55) | none | α2a: 180 μg | 1000-1200 | ||
[11] McHutchison et al. 2010 | Experienced | FLT | 24 | C | 115 | 51 | 78 (68) | 33 (29) | 12 | α2a: 180 μg | 1000-1200 |
FLT | 48 | B | 113 | 52 | 80 (71) | 42 (37) | 24 | α2a: 180 μg | 1000-1200 | ||
FLT | 24 | NI | 111 | 53 | 72 (65) | 36 (32) | 24 | α2a: 180 μg | none | ||
Control | 48 | A | 114 | 50 | 76 (67) | 34 (30) | none | α2a: 180 μg | 1000-1200 | ||
[10] Jacobson et al. 2011 | Naïve | RGT | 24 (+24) | D | 363 | 49 | 214 (59) | 149 (41) | 12 | α2a: 180 μg | 1000-1200 |
RGT | 24 (+24) | NI | 364 | 49 | 211 (58) | 151 (41) | 8 | α2a: 180 μg | 1000-1200 | ||
Control | 48 | A | 361 | 49 | 211 (58) | 151 (42) | none | α2a: 180 μg | 1000-1200 | ||
[13] Zeuzem et al. | Experienced | FLT | 48 | B | 266 | 51 | 183 (69) | 121 (45) | 12 | α2a: 180 μg | 1000-1200 |
FLT | 48 | NI | 264 | 51 | 189 (72) | 115 (44) | 16 | α2a: 180 μg | 1000-1200 | ||
Control | 48 | A | 132 | 50 | 88 (67) | 59 (45) | none | α2a: 180 μg | 1000-1200 | ||
[17] Sherman et al. 2011 | Naïve | RGT | 24 (+24) | D | 221 | NA | NA | NA | 12 | α2a: 180 μg | 1000-1200 |
FLT | 48 | B | 219 | NA | NA | NA | 12 | α2a: 180 μg | 1000-1200 | ||
[15] Kumada et al. 2012 | Naïve | FLT | 24 | C | 126 | 53 | 66 (52) | 124 (98) | 12 | α2b: 1.5 μg/kg | 600-1000 |
Control | 48 | A | 63 | 55 | 33 (52) | 63 (100) | none | α2b: 1.5 μg/kg | 600-1000 |